Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered paper session - Breast cancer, metastatic

3578 - Patient-reported outcomes (PRO) in patients (pts) with advanced breast cancer and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy treatment (PCT): a focus on the EMBRACA triple negative (TNBC) subpopulation


20 Oct 2018


Proffered paper session - Breast cancer, metastatic


Genetic Testing and Counselling;  Cytotoxic Therapy;  Targeted Therapy;  Genetic and Genomic Testing

Tumour Site

Breast Cancer


Hope Rugo


Annals of Oncology (2018) 29 (suppl_8): viii90-viii121. 10.1093/annonc/mdy272


H.S. Rugo1, R. Quek2, J. Ettl3, S.A. Hurvitz4, H. Bhattacharyya2, A.L. Hannah5, J.K. Litton6

Author affiliations

  • 1 Breast Cancer Center, UCSF Helen Diller Family Comprehensive Cancer Center, 94115 - San Francisco/US
  • 2 Health Economics, Pfizer, Inc., 94080 - San Francisco/US
  • 3 Obs Gyn, Technische Universität München, 80333 - Munich/DE
  • 4 Hematology/oncology, University of California, Los Angeles, 90404 - Santa Monica/US
  • 5 Oncology, Pfizer, Inc., 94080 - San Francisco/US
  • 6 Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 77030 - Houston/US


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3578


As part of the key subgroup analyses of EMBRACA, a randomised 2:1 open-label phase 3 study, a statistically significant improvement in progression-free survival (PFS) with TALA (n = 130) vs PCT (n = 60) (median PFS 5.8 vs 2.9 mos, HR = 0.60; 95% CI 0.41-0.87, P=.008) was observed in pts with advanced TNBC and gBRCAm; these post hoc analyses evaluated PRO.


PRO were assessed on day 1 (baseline), at the start of each treatment cycle (every 3 wks), and end of treatment using questionnaires (EORTC QLQ-C30 and breast cancer module, QLQ-BR23). Higher scores indicate better functioning/global health status/quality of life (GHS)/(QoL) or worse symptom severity. Repeated measures mixed-effects analyses were performed to compare overall change from baseline scores between the 2 treatment arms, controlling for baseline. Time to definitive deterioration (TDD) (change of ≥ 10 points) in GHS/QoL and pain symptoms were compared using stratified log-rank test and Cox proportional hazards model.


Baseline scores were similar between arms. A statistically significant overall change from baseline in GHS/QoL favoured TALA vs PCT (12.5 [95% CI 7.1-17.8], P<.0001). Additionally, TALA resulted in a statistically significant favourable difference in overall change from baseline in the following functions: physical, role, social, body image and the symptoms: fatigue, pain, appetite loss, breast and arm. No significant differences were observed between arms for emotional and cognitive functioning, nausea/vomiting, dyspnea, insomnia, constipation, diarrhoea, upset by hair loss, sexual enjoyment and functioning. A statistically significant delay in TTD favouring TALA was observed in GHS/QoL [median 24.3 vs 4.5 mos, hazard ration 0.33 (95% CI 0.19-0.57); P<.0001] and pain [median 22.7 vs 5.6 mos, HR = 0.25 (95% CI 0.14-0.45), P<.0001].


In pts with gBRCAm advanced TNBC, TALA resulted in significantly greater improvement from baseline and delayed TTD in GHS/QoL and pain symptom vs PCT.

Clinical trial identification


Legal entity responsible for the study

Pfizer, Inc.


Pfizer, Inc.

Editorial Acknowledgement

Editorial and medical writing support funded by Pfizer Inc. were provided by Edwin Thrower, PhD, Mary Kacillas and Paula Stuckart of Ashfield Healthcare Communications, Middletown, Connecticut.


H.S. Rugo: Fees for contracted research to the University of California: Eisai, Genentech, GSK, Lilly, Macrogenics, Merck, Novartis, OBI Pharma, Pfizer, Plexxikon; Travel: Lilly, Mylan, Puma R. Quek, H. Bhattacharyya: Employee of Pfizer Inc. J. Ettl: Consulting fees: Novartis, Pfizer, Roche, and Eisai; Contracted research: Celgene; Honoraria: Pfizer, Roche, Teva and Pierre Fabre. S.A. Hurvitz: Contracted research: Amgen, Bayer, BioMarin, BI, Cascadian Therapeutics, Dignitana, Genentech/Roche, GSK, Lilly, Medivation, Merrimack, Novartis, OBI Pharma, Pfizer, Puma Biotechnology and Sanofi; Travel: Bayer, Lilly, Novartis, OBI Pharma. A.L. Hannah: Consulting fees: Basilea, Medivation/Pfizer and Nektar; Ownership interest in NeoGenomics Laboratories. J.K. Litton: Institutional-contracted research: Pfizer, Novartis, EMD-Serono, AstraZeneca, GlaxoSmithKline and Genentech; Advisory board participation: AstraZeneca and Pfizer, both uncompensated.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.